Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327691 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 8,600
- Enrollment target
NCT00327691: Completed Phase 4 study, sponsored by Pfizer.
NCT00327691 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 8,600 participants, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1563% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00327691, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8,600 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.
Interventions
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,600 participants |
| Start Date | 1998-04 |
| Est. Completion | 2004-08 |
| Phase | Phase 4 |
What the finished NCT00327691 record still lists
NCT00327691 is an interventional study that assigns participants to a tested intervention. Its 8,600 participants enrollment target places it among the larger protocols in the corpus, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1563% higher).
The record links to 0 conditions, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00327691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00327691 about?
NCT00327691 is a clinical study titled "A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels". The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of...
What is the current status of trial NCT00327691?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8,600 participants. The study started on 1998-04. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00327691?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00327691?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00327691's enrollment target sits among peer trials
8,600 9th of 2000 higher than 1,991 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia